Page last updated: 2024-08-17

quinoxalines and erdafitinib

quinoxalines has been researched along with erdafitinib in 71 studies

Research

Studies (71)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	21 (29.58)	24.3611
2020's	50 (70.42)	2.80

Authors

Authors	Studies
Belaid, H; Boisselier, B; Bruno, A; Chan, JA; Di Stefano, AL; Eoli, M; Finocchiaro, G; Frattini, V; Fucci, A; Giry, M; Houillier, C; Iavarone, A; Idbaih, A; Kamoun, A; Labussiere, M; Lasorella, A; Luo, FR; Marie, Y; Mokhtari, K; Paterra, R; Petrecca, K; Sanson, M; Savatovsky, J; Soria, JC; Tabernero, J; Touat, M; Yip, S; Zoppoli, P	1
André, F; Cortés, J	1
Adamo, B; Bahleda, R; Calvo, E; Chatterjee-Kishore, M; Dienstmann, R; Gazzah, A; Infante, JR; Italiano, A; Luo, FR; Mita, A; Moreno, V; Peddareddigari, V; Platero, SJ; Rodon, J; Smit, JW; Soria, JC; Stuyckens, K; Tabernero, J; Zhong, B	1
Debucquoy, A; Devos, E; Dok, R; Gonnissen, A; Haustermans, K; Isebaert, S; McBride, W; Verstraete, M	1
Bastaros, JM; Carles, J; de Castro, AM; Maldonado, X; Morales-Barrera, R; Morote, J; Racca, F; Suárez, C; Valverde, C	1
Angibaud, P; Cheng, N; De Lange, D; Freyne, E; Gilissen, R; Jovcheva, E; Karkera, JD; King, P; Laquerre, S; Lorenzi, MV; Mevellec, L; Moy, C; Murray, CW; Newell, DR; Page, M; Paulussen, C; Perera, TPS; Platero, SJ; Rees, DC; Saxty, G; Squires, M; Thompson, NT; Van De Ven, K; Verhulst, T; Vialard, J; Ward, G; Xie, L; Yang, J	1
Alvarez, JD; Bahleda, R; Bell, K; Cardona, GM; Gaffney, D; Karkera, JD; King, P; Lorenzi, MV; Luo, FR; Moy, CH; Platero, SJ; Portale, JC; Santiago-Walker, A; Sharp, M	1
Bétrian, S; Delord, JP; Gomez-Roca, C; Sibaud, V; Vigarios, E	1
Cousin, S; Italiano, A; Leroy, L	1
Aoki, M; Doi, T; Iwasawa, R; Nishina, T; Noguchi, H; Takahashi, S	1
Cortes, J; Muñoz-Couselo, E; Perez-Garcia, J; Racca, F; Soberino, J	1
Arteaga, CL; Balko, JM; Bardia, A; Bauer, JA; Behdad, A; Cristofanilli, M; Croessmann, S; Cruz, MR; Dugger, TC; Ericsson, PG; Formisano, L; Guerrero-Zotano, AL; Guo, Y; Hanker, AB; He, W; Jansen, VM; Lanman, RB; Lee, KM; Lu, Y; Mayer, IA; Miller, M; Nagy, RJ; Nixon, MJ; O'Shaughnessy, J; Sanders, ME; Schwarz, LJ; Servetto, A; Shyr, Y; Solovieff, N; Su, F; Sudhan, DR	1
Awad, M; Bahleda, R; Calvo, E; Cervantes, A; Chan, N; Gonzalez, M; Govindan, R; Hierro, C; Infante, J; Italiano, A; Mita, A; Moreno, V; Parekh, T; Poggesi, I; Santiago-Walker, A; Spira, A; Tabernero, J; Xie, H; Zhong, B	1
Markham, A	1
Chen, Y; Chen, Z; Dai, S; Xu, G; Zhou, Z	1
Dosne, AG; Kleiman, R; Li, LY; Ouellet, D; Perez-Ruixo, JJ; Valade, E; Xie, H	1
Avadhani, A; Burgess, E; De Porre, P; Duran, I; Fleming, M; Garcia-Donas, J; Huddart, R; Joshi, M; Loriot, Y; Mellado, B; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh, A; Santiago-Walker, A; Siefker-Radtke, AO; Stuyckens, K; Tagawa, ST; Varlamov, S; Zakharia, Y; Zhong, B	1
Burki, TK	1
Hanna, KS	1
Gonzalez, M; Guo, Y; Li, LY; Ouellet, D	1
De Meulder, M; de Zwart, L; Hellemans, P; Jiao, J; Li, LY; Mamidi, RNVS; Ouellet, D; Poggesi, I; Rasschaert, F; Snoeys, J	1
Castelli, R; Lodola, A; Marseglia, G; Mor, M	1
Chang, SS	1
Dosne, AG; Li, LY; Ouellet, D; Perez-Ruixo, JJ; Stuyckens, K; Valade, E	1
de Almeida Carvalho, LM; de Oliveira Sapori Avelar, S; Gill, J; Haslam, A; Prasad, V	1
Bellmunt, J; Montazeri, K	1
Kolesar, JM; Myint, ZW; Roubal, K	1
Grülllich, C	1
Lebenthal, J; Nauseef, JT; Tagawa, ST; Villamar, DM; Vlachostergios, PJ	1
Carles, J; González, M; Maldonado, X; Mateo, J; Morales-Barrera, R; Morote, J; Raventos, C; Serra, E; Suárez, C; Valverde, C	1
Burgess, M; English, A; Hartmann, A; Major, C; Sweeney, M; Wang, S	1
Galsky, MD; Patel, V; Qin, Q	1
Amir, M; Javed, S; Qureshi, MA	1
Ertl, IE; Ilijazi, D; Loriot, Y; Mostafaei, H; Shariat, SF	1
Annan, RS; Bamborough, P; Bush, JT; Chung, CW; Dixon, DP; Fallon, DJ; Fantom, KGM; Grant, EK; Hann, MM; House, D; Patel, VK; Quinn, C; Stacey, P; Tomkinson, NCO; Zappacosta, F	1
Eliott, D; Kim, LA; Parikh, D	1
Boyle, TA; Haura, EB; Hicks, JK	1
Bagby, S; Bortoletti, C; D'Angelo, A; Galli, IC; Roviello, G	1
Bednova, O; Leyton, JV	1
Cleary, JM; Hirner, J; LeBoeuf, N; Murphy, G; Sheets, A	1
Babiker, HM; Chandana, SR; Mahadevan, D	1
Bauters, G; Borderie, V; Bouheraoua, N; Paques, M	1
Montazeri, K; Sonpavde, G	1
Bugatti, M; Di Trani, M; Giacomini, A; Grillo, E; Guerra, J; Matarazzo, S; Presta, M; Rezzola, S; Ronca, R; Scotuzzi, A; Taranto, S	1
Bossaer, JB; Weaver, A	1
Bansal, P; Dwivedi, DK; Goyal, S; Gupta, V; Hatwal, D; Maithani, M; Sharma, P	1
Dalianis, T; Herold, N; Holzhauser, S; Kostopoulou, ON; Lukoseviciute, M; Papachristofi, C; Vasilopoulou, C; Wickström, M	1
Comet, A; Denis, D; Ramtohul, P	1
Al-Obaidy, KI; Cheng, L	1
Belal, F; El-Enany, N; Elawady, T; Khedr, A	2
Alberts, AR; Iflé, IG; Scholtes, MP; van der Veldt, AAM; Verhagen, PCMS; Zuiverloon, TCM	1
Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A	1
Kim, HS; Seo, HK	1
Chan, ECY; Go, ML; Koh, SK; Tang, LWT; Teng, JW; Zhou, L	1
Javle, M; King, G	1
De Zwart, L; Goris, I; Jacobs, F; Li, LY; Mamidi, RNVS; Monshouwer, M; Poggesi, I; Scheers, E; Snoeys, J; Verboven, P; Wynant, I	1
Khor, D; Poon, D; Tan, MH	1
Avadhani, A; De Porre, P; Dosne, AG; Faelens, R; Leirens, Q; Li, LY; O'Hagan, A; Ouellet, D; Perez Ruixo, JJ; Poggesi, I; Stuyckens, K; Valade, E	1
Dosne, AG; King, P; Magni, P; Perera, T; Perez-Ruixo, JJ; Poggesi, I; Stuyckens, K; Terranova, N; Tosca, EM; Verhulst, T; Vialard, J	1
Claiborne, RT; Tsan, GL	1
Avadhani, A; De Porre, P; Dosne, AG; Goeyvaerts, N; Li, LY; O'Hagan, A; Ouellet, D; Perez Ruixo, JJ; Valade, E	1
Akapame, S; Burgess, EF; Duran, I; Fleming, MT; García-Donas, J; Huddart, RA; Joshi, M; Loriot, Y; Mellado, B; Monga, M; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh Kalebasty, A; Santiago-Walker, AE; Siefker-Radtke, AO; Tagawa, ST; Varlamov, S; Zakharia, Y	1
Loriot, Y; Siefker-Radtke, AO	1
Hu, C; Hu, X; Shang, X; Zhao, Y; Zheng, T	1
Cosmai, L; Franza, A; Giannatempo, P; Pirovano, M	1
Bauman, JE; Lawson-Michod, KA; Le, CH; Thomas, PC; Tranesh, G	1
Arai, S; Fujizuka, Y; Kato, M; Koike, H; Maeno, Y; Matsui, H; Miyazawa, Y; Ohtsu, A; Sawada, T; Sekine, Y; Suzuki, K	1
Ji, J; Li, X; Meng, X; Shu, H; Wang, K; Wang, X; Xie, G; Zhao, H; Zhong, H; Zhu, X	1
Glaspy, J; Gong, J; Hendifar, AE; Moshayedi, N; Ng, CF; Osipov, A; Placencio-Hickok, VR; Thomassian, S	1
Aggarwal, C; Gandhi, N; Grant, NN; Halmos, B; Kim, C; Krochmal, R; Liu, SV; Reuss, JE; Sackstein, P; Yeung, V	1

Reviews

24 review(s) available for quinoxalines and erdafitinib

Article	Year
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast cancer research and treatment, 2015, Volume: 150, Issue:1 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction; Treatment Outcome	2015
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer treatment reviews, 2016, Volume: 50 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Ipilimumab; Nivolumab; Phenylurea Compounds; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms	2016
Targeting FGFR pathway in breast cancer. Breast (Edinburgh, Scotland), 2018, Volume: 37 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblast Growth Factors; Humans; Naphthalenes; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinolines; Quinolones; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction	2018
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors. Cells, 2019, 06-18, Volume: 8, Issue:6 Topics: Fibroblast Growth Factors; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Signal Transduction	2019
Erdafitinib to treat urothelial carcinoma. Drugs of today (Barcelona, Spain : 1998), 2019, Volume: 55, Issue:8 Topics: Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Urologic Neoplasms; Urothelium	2019
Fibroblast growth factor receptor inhibitors: patent review (2015-2019). Expert opinion on therapeutic patents, 2019, Volume: 29, Issue:12 Topics: Animals; Antineoplastic Agents; Drug Development; Humans; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2019
Erdafitinib for the treatment of metastatic bladder cancer. Expert review of clinical pharmacology, 2020, Volume: 13, Issue:1 Topics: Animals; Carcinoma, Transitional Cell; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms	2020
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2020, Feb-19, Volume: 77, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms	2020
[High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy]. Der Urologe. Ausg. A, 2020, Volume: 59, Issue:4 Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Treatment Outcome; Urologic Neoplasms; Urothelium	2020
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:8 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Molecular Targeted Therapy; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms	2020
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. Cancer treatment reviews, 2020, Volume: 86 Topics: Antineoplastic Agents; Humans; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms	2020
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. Expert review of anticancer therapy, 2020, Volume: 20, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Development; Humans; Immune Checkpoint Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Urinary Bladder Neoplasms	2020
Fibroblast growth factor receptors across urothelial carcinoma landscape. Current opinion in urology, 2020, Volume: 30, Issue:4 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms	2020
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand. Expert review of clinical pharmacology, 2020, Volume: 13, Issue:10 Topics: Administration, Oral; Adult; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Disease Progression; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms	2020
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors? International journal of molecular sciences, 2020, Oct-01, Volume: 21, Issue:19 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; B7-H1 Antigen; Camptothecin; Cell Adhesion Molecules; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy; Lymphatic Metastasis; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Pyrazoles; Quinoxalines; Urinary Bladder; Urinary Bladder Neoplasms	2020
Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics. Expert opinion on investigational drugs, 2020, Volume: 29, Issue:12 Topics: Animals; Antineoplastic Agents; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Morpholines; Neoplasms; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, Fibroblast Growth Factor	2020
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. Expert review of anticancer therapy, 2021, Volume: 21, Issue:3 Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms	2021
Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:3 Topics: Bile Duct Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3	2021
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma. Anti-cancer agents in medicinal chemistry, 2021, Volume: 21, Issue:18 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms	2021
Fibroblast growth factor receptor ( Journal of clinical pathology, 2021, Volume: 74, Issue:8 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium	2021
Biomarker-Oriented Therapy in Bladder and Renal Cancer. International journal of molecular sciences, 2021, Mar-11, Volume: 22, Issue:6 Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Kidney Neoplasms; Lymphatic Metastasis; Mutation; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Recurrence; Urinary Bladder Neoplasms	2021
Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer. Investigative and clinical urology, 2021, Volume: 62, Issue:4 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Genes, Viral; Genetic Therapy; Humans; Hyperthermia; Immune Checkpoint Inhibitors; Immunoconjugates; Organ Sparing Treatments; Photochemotherapy; Pyrazoles; Quinoxalines; Retreatment; Treatment Failure; Urinary Bladder Neoplasms	2021
FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. Current oncology reports, 2021, 07-16, Volume: 23, Issue:9 Topics: Aniline Compounds; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Clinical Trials as Topic; Humans; Morpholines; Mutation; Phenylurea Compounds; Precision Medicine; Pyrazoles; Pyrimidines; Pyrroles; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction	2021
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain Future oncology (London, England), 2022, Volume: 18, Issue:19 Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms	2022

Trials

10 trial(s) available for quinoxalines and erdafitinib

Article	Year
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Jul-15, Volume: 21, Issue:14 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; Female; Fluorescent Antibody Technique; Glioma; Humans; Immunohistochemistry; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Molecular Targeted Therapy; Oncogene Proteins, Fusion; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays	2015
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Oct-20, Volume: 33, Issue:30 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2015
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Investigational new drugs, 2018, Volume: 36, Issue:3 Topics: Aged; Area Under Curve; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome	2018
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 08-15, Volume: 25, Issue:16 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Retreatment; Treatment Outcome; Young Adult	2019
Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors. Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Electrocardiography; Female; Follow-Up Studies; Heart; Heart Rate; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Prognosis; Pyrazoles; Quinoxalines; Tissue Distribution; Young Adult	2019
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. The New England journal of medicine, 2019, 07-25, Volume: 381, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Metastasis; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urologic Neoplasms; Urothelium	2019
Erdafitinib for advanced urothelial carcinoma. The Lancet. Oncology, 2019, Volume: 20, Issue:9 Topics: Carcinoma, Transitional Cell; Drug-Related Side Effects and Adverse Reactions; Humans; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms; Urothelium	2019
Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study. European journal of drug metabolism and pharmacokinetics, 2020, Volume: 45, Issue:1 Topics: Adult; Area Under Curve; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme Inhibitors; Drug Combinations; Drug Interactions; Female; Fluconazole; Healthy Volunteers; Humans; Itraconazole; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2020
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:2 Topics: Aged; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Survival Rate; Urinary Bladder Neoplasms	2022
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study. The Lancet. Oncology, 2022, Volume: 23, Issue:2 Topics: Aged; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; ErbB Receptors; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms	2022

Other Studies

37 other study(ies) available for quinoxalines and erdafitinib

Article	Year
In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC cancer, 2015, Dec-16, Volume: 15 Topics: Animals; Apoptosis; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Humans; In Vitro Techniques; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays	2015
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor. Molecular cancer therapeutics, 2017, Volume: 16, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Humans; Lysosomes; Male; Mice; Molecular Targeted Therapy; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays	2017
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib. Molecular cancer therapeutics, 2017, Volume: 16, Issue:8 Topics: Animals; Biomarkers, Tumor; Male; Oncogene Proteins, Fusion; Oncogenes; Pyrazoles; Quinoxalines; Rats, Nude; Receptors, Fibroblast Growth Factor; Tomography, X-Ray Computed; Urinary Bladder Neoplasms	2017
Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors. JAMA dermatology, 2017, 07-01, Volume: 153, Issue:7 Topics: Eyelashes; Eyelid Diseases; Fibroblast Growth Factors; Glioblastoma; Humans; Male; Middle Aged; Onycholysis; Pyrazoles; Quinoxalines; Severity of Illness Index; Urinary Bladder Neoplasms	2017
Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours. European journal of cancer (Oxford, England : 1990), 2017, Volume: 81 Topics: Aged; Aniline Compounds; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Treatment Outcome	2017
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature communications, 2019, 03-26, Volume: 10, Issue:1 Topics: Aminopyridines; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; MCF-7 Cells; Mice; Mutation; Naphthalenes; Piperazines; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Quinolines; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays	2019
Erdafitinib: First Global Approval. Drugs, 2019, Volume: 79, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Approval; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms	2019
Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross-Study Analysis. Journal of clinical pharmacology, 2020, Volume: 60, Issue:3 Topics: Adolescent; Adult; Area Under Curve; Blood Proteins; Clinical Trials, Phase I as Topic; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Orosomucoid; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Serum Albumin, Human; Young Adult	2020
Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. The Journal of urology, 2020, Volume: 203, Issue:2 Topics: Carcinoma, Transitional Cell; Humans; Pyrazoles; Quinoxalines; Urologic Neoplasms	2020
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies. Journal of clinical pharmacology, 2020, Volume: 60, Issue:4 Topics: Administration, Oral; Adult; Aged; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Drug Administration Schedule; Female; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines	2020
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib. JAMA network open, 2019, 11-01, Volume: 2, Issue:11 Topics: Antineoplastic Agents; Genetic Variation; Humans; Neoplasms; Off-Label Use; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms	2019
Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment. The journal of pathology. Clinical research, 2020, Volume: 6, Issue:3 Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Pyrazoles; Quinoxalines; Real-Time Polymerase Chain Reaction; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urologic Neoplasms	2020
Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin. Journal of biomolecular structure & dynamics, 2021, Volume: 39, Issue:11 Topics: Binding Sites; Carcinoma, Transitional Cell; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Tumor Microenvironment; Urinary Bladder Neoplasms	2021
A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands. Angewandte Chemie (International ed. in English), 2020, 11-16, Volume: 59, Issue:47 Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cross-Linking Reagents; Humans; Ligands; Molecular Structure; Photoaffinity Labels; Proteins; Pyrazoles; Quinoxalines; Sulfonamides; Vemurafenib	2020
Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. JAMA ophthalmology, 2020, 10-01, Volume: 138, Issue:10 Topics: Adenocarcinoma; Fluorescein Angiography; Fundus Oculi; Humans; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Retina; Retinal Diseases; Stomach Neoplasms; Tomography, Optical Coherence; Visual Acuity	2020
Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2020, Volume: 15, Issue:9 Topics: Acrylamides; Aniline Compounds; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3	2020
Fibroblast Growth Factor Receptor Inhibitors and Nonuremic Calciphylaxis. JAMA dermatology, 2021, 01-01, Volume: 157, Issue:1 Topics: Aged; Bile Duct Neoplasms; Biopsy; Calciphylaxis; Cholangiocarcinoma; Female; Humans; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Skin; Thigh	2021
Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: Report of three cases. Journal francais d'ophtalmologie, 2021, Volume: 44, Issue:1 Topics: Cataract; Glaucoma, Angle-Closure; Humans; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Retrospective Studies	2021
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. International journal of molecular sciences, 2020, Dec-09, Volume: 21, Issue:24 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cholesterol; Down-Regulation; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Oxidative Stress; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2020
Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. International journal of oncology, 2021, Volume: 58, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Cisplatin; Cytostatic Agents; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Neuroblastoma; Phosphoinositide-3 Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Thiazoles; Vincristine	2021
Pseudovitelliform Maculopathy Associated with FGFR Inhibitor Therapy. Ophthalmology. Retina, 2021, Volume: 5, Issue:2 Topics: Aged, 80 and over; Fluorescein Angiography; Fundus Oculi; Humans; Macula Lutea; Macular Degeneration; Male; Pyrazoles; Quinoxalines; Tomography, Optical Coherence; Urologic Neoplasms	2021
HPLC-UV determination of erdafitinib in mouse plasma and its application to pharmacokinetic studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021, May-01, Volume: 1171 Topics: Animals; Chromatography, High Pressure Liquid; Limit of Detection; Linear Models; Mice; Pyrazoles; Quinoxalines; Reproducibility of Results	2021
FGFR alterations in urothelial carcinoma: Picking the right target. Bulletin du cancer, 2021, Volume: 108, Issue:6 Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms	2021
Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. Chemical research in toxicology, 2021, 07-19, Volume: 34, Issue:7 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Humans; NADP; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2021
Prediction of the drug-drug interaction potential of the α1-acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:9 Topics: Antineoplastic Agents; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Genotype; Humans; Models, Biological; Orosomucoid; Pyrazoles; Quinoxalines	2021
Stage 4 pancreatic adenocarcinoma harbouring an BMJ case reports, 2021, Sep-12, Volume: 14, Issue:9 Topics: Adenocarcinoma; Aged; Carrier Proteins; Female; Humans; Mutation; Pancreatic Neoplasms; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Tumor Suppressor Proteins	2021
Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer. CPT: pharmacometrics & systems pharmacology, 2022, Volume: 11, Issue:5 Topics: Female; Humans; Neoplasms; Phosphates; Pyrazoles; Quinoxalines	2022
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:1 Topics: Animals; Clinical Trials, Phase I as Topic; Humans; Mice, Nude; Models, Biological; Pyrazoles; Quinoxalines; Rats; Translational Research, Biomedical; Xenograft Model Antitumor Assays	2022
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy. Optometry and vision science : official publication of the American Academy of Optometry, 2022, 01-01, Volume: 99, Issue:1 Topics: Aged, 80 and over; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazoles; Quality of Life; Quinoxalines; Receptors, Fibroblast Growth Factor; United States; Urinary Bladder Neoplasms	2022
Erdafitinib for locally advanced or metastatic urothelial carcinoma. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 05-24, Volume: 79, Issue:11 Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms	2022
Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells. Biochemical and biophysical research communications, 2022, 05-14, Volume: 604 Topics: Apoptosis; Bcl-2-Like Protein 11; Humans; Mitochondria; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinoxalines; Receptors, Fibroblast Growth Factor; Up-Regulation; Urinary Bladder Neoplasms	2022
Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor "Erdafitinib": Application to human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2022, Oct-05, Volume: 278 Topics: Carcinoma, Transitional Cell; Humans; Micelles; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Solvents; Spectrometry, Fluorescence; Urinary Bladder Neoplasms	2022
Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma. Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:10 Topics: Adult; Ameloblastoma; B7-H1 Antigen; Humans; Male; Precision Medicine; Pyrazoles; Quality of Life; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2	2022
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells. Biochemical and biophysical research communications, 2022, 11-05, Volume: 628 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Carcinoma, Transitional Cell; Cell Line, Tumor; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor	2022
Erdafitinib Inhibits Tumorigenesis of Human Lung Adenocarcinoma A549 by Inducing S-Phase Cell-Cycle Arrest as a CDK2 Inhibitor. Molecules (Basel, Switzerland), 2022, Oct-09, Volume: 27, Issue:19 Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Carcinogenesis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines	2022
Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network : JNCCN, 2022, Volume: 20, Issue:10 Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Humans; Pancreatic Neoplasms; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Tumor Microenvironment	2022
Use of Erdafitinib in JCO precision oncology, 2022, Volume: 6 Topics: Humans; Papillomavirus Infections; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Respiratory Tract Infections	2022